News

Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...
Applied Clinical Trials Online8h

Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...
Healio12h

New treatments for diabetes, obesity take center stage at ADA

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage

Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NA ...
The Manila Times15h

Merakris Therapeutics Receives USPTO Notice of Allowance for Foundational Patent Supporting MTX-001 Biologic Drug Platform

Patent strengthens intellectual property for investigational new drug MTX-001 - Phase 2 clinical trial for chronic venous leg ulcers ongoing ...
The Manila Times16h

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the 'Company'), a clinical-stage biopharmaceutical company focused on its Phase ...

Basilea Pharmaceutica AG: Basilea on track with strong 2025 half-year results

Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash fl ...